High-fat diet impairs duodenal barrier function and elicits glia-dependent changes along the gut-brain axis that are required for anxiogenic and depressive-like behaviors.
Behavioral disorders
Enteric glia
Glial signaling
Gut-brain axis
High-fat diet
Intestinal hyper-permeability
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
16 May 2021
16 May 2021
Historique:
received:
17
12
2020
accepted:
30
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Mood and metabolic disorders are interrelated and may share common pathological processes. Autonomic neurons link the brain with the gastrointestinal tract and constitute a likely pathway for peripheral metabolic challenges to affect behaviors controlled by the brain. The activities of neurons along these pathways are regulated by glia, which exhibit phenotypic shifts in response to changes in their microenvironment. How glial changes might contribute to the behavioral effects of consuming a high-fat diet (HFD) is uncertain. Here, we tested the hypothesis that anxiogenic and depressive-like behaviors driven by consuming a HFD involve compromised duodenal barrier integrity and subsequent phenotypic changes to glia and neurons along the gut-brain axis. C57Bl/6 male mice were exposed to a standard diet or HFD for 20 weeks. Bodyweight was monitored weekly and correlated with mucosa histological damage and duodenal expression of tight junction proteins ZO-1 and occludin at 0, 6, and 20 weeks. The expression of GFAP, TLR-4, BDNF, and DCX were investigated in duodenal myenteric plexus, nodose ganglia, and dentate gyrus of the hippocampus at the same time points. Dendritic spine number was measured in cultured neurons isolated from duodenal myenteric plexuses and hippocampi at weeks 0, 6, and 20. Depressive and anxiety behaviors were also assessed by tail suspension, forced swimming, and open field tests. HFD mice exhibited duodenal mucosa damage with marked infiltration of immune cells and decreased expression of ZO-1 and occludin that coincided with increasing body weight. Glial expression of GFAP and TLR4 increased in parallel in the duodenal myenteric plexuses, nodose ganglia, and hippocampus in a time-dependent manner. Glial changes were associated with a progressive decrease in BDNF, and DCX expression, fewer neuronal dendritic spines, and anxiogenic/depressive symptoms in HFD-treated mice. Fluorocitrate (FC), a glial metabolic poison, abolished these effects both in the enteric and central nervous systems and prevented behavioral alterations at week 20. HFD impairs duodenal barrier integrity and produces behavioral changes consistent with depressive and anxiety phenotypes. HFD-driven changes in both peripheral and central nervous systems are glial-dependent, suggesting a potential glial role in the alteration of the gut-brain signaling that occurs during metabolic disorders and psychiatric co-morbidity.
Sections du résumé
BACKGROUND
BACKGROUND
Mood and metabolic disorders are interrelated and may share common pathological processes. Autonomic neurons link the brain with the gastrointestinal tract and constitute a likely pathway for peripheral metabolic challenges to affect behaviors controlled by the brain. The activities of neurons along these pathways are regulated by glia, which exhibit phenotypic shifts in response to changes in their microenvironment. How glial changes might contribute to the behavioral effects of consuming a high-fat diet (HFD) is uncertain. Here, we tested the hypothesis that anxiogenic and depressive-like behaviors driven by consuming a HFD involve compromised duodenal barrier integrity and subsequent phenotypic changes to glia and neurons along the gut-brain axis.
METHODS
METHODS
C57Bl/6 male mice were exposed to a standard diet or HFD for 20 weeks. Bodyweight was monitored weekly and correlated with mucosa histological damage and duodenal expression of tight junction proteins ZO-1 and occludin at 0, 6, and 20 weeks. The expression of GFAP, TLR-4, BDNF, and DCX were investigated in duodenal myenteric plexus, nodose ganglia, and dentate gyrus of the hippocampus at the same time points. Dendritic spine number was measured in cultured neurons isolated from duodenal myenteric plexuses and hippocampi at weeks 0, 6, and 20. Depressive and anxiety behaviors were also assessed by tail suspension, forced swimming, and open field tests.
RESULTS
RESULTS
HFD mice exhibited duodenal mucosa damage with marked infiltration of immune cells and decreased expression of ZO-1 and occludin that coincided with increasing body weight. Glial expression of GFAP and TLR4 increased in parallel in the duodenal myenteric plexuses, nodose ganglia, and hippocampus in a time-dependent manner. Glial changes were associated with a progressive decrease in BDNF, and DCX expression, fewer neuronal dendritic spines, and anxiogenic/depressive symptoms in HFD-treated mice. Fluorocitrate (FC), a glial metabolic poison, abolished these effects both in the enteric and central nervous systems and prevented behavioral alterations at week 20.
CONCLUSIONS
CONCLUSIONS
HFD impairs duodenal barrier integrity and produces behavioral changes consistent with depressive and anxiety phenotypes. HFD-driven changes in both peripheral and central nervous systems are glial-dependent, suggesting a potential glial role in the alteration of the gut-brain signaling that occurs during metabolic disorders and psychiatric co-morbidity.
Identifiants
pubmed: 33993886
doi: 10.1186/s12974-021-02164-5
pii: 10.1186/s12974-021-02164-5
pmc: PMC8126158
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK103723
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK120862
Pays : United States
Références
J Neurochem. 1987 May;48(5):1377-85
pubmed: 3559554
Eur J Pharmacol. 2018 Jan 5;818:578-584
pubmed: 29162434
Acta Physiol (Oxf). 2014 Nov;212(3):226-38
pubmed: 25164090
Am J Physiol Gastrointest Liver Physiol. 2011 Jun;300(6):G976-87
pubmed: 21350188
FASEB J. 2020 Apr;34(4):5512-5524
pubmed: 32086846
Gastroenterology. 2015 Aug;149(2):445-55.e3
pubmed: 25865048
Sci Rep. 2017 Aug 10;7(1):7735
pubmed: 28798420
Gut. 2014 Jan;63(1):105-15
pubmed: 23292665
Front Cell Neurosci. 2019 Feb 08;13:30
pubmed: 30800058
Gastroenterology. 2007 Apr;132(4):1344-58
pubmed: 17408650
Appetite. 2013 Apr;63:119-28
pubmed: 23291218
PLoS One. 2019 Feb 22;14(2):e0212856
pubmed: 30794676
Front Neurosci. 2015 Jul 03;9:229
pubmed: 26190966
Nat Neurosci. 2006 Oct;9(10):1294-301
pubmed: 16980967
Glia. 2021 Jan;69(1):42-60
pubmed: 32659044
J Clin Invest. 2015 Mar 2;125(3):888-90
pubmed: 25729849
Nat Protoc. 2007;2(6):1490-8
pubmed: 17545985
Cell Mol Gastroenterol Hepatol. 2016 Jan 1;2(1):77-91
pubmed: 26771001
Front Neurosci. 2018 Oct 10;12:725
pubmed: 30364179
Glia. 1997 Sep;21(1):106-13
pubmed: 9298853
Neural Regen Res. 2020 Jun;15(6):1037-1038
pubmed: 31823880
Expert Rev Clin Pharmacol. 2019 Jun;12(6):555-564
pubmed: 31025582
Schizophr Res. 2005 Dec 15;80(2-3):323-30
pubmed: 16140506
Am J Physiol Gastrointest Liver Physiol. 2004 Jun;286(6):G1009-14
pubmed: 14739140
Physiology (Bethesda). 2018 Jul 1;33(4):269-280
pubmed: 29897300
Nutr Neurosci. 2019 Dec;22(12):877-893
pubmed: 29697017
Neurogastroenterol Motil. 2011 Dec;23(12):1132-9
pubmed: 21988661
Science. 2020 Oct 16;370(6514):314-321
pubmed: 32855216
J Vis Exp. 2014 Nov 25;(93):e52233
pubmed: 25490160
Nature. 2016 Jul 21;535(7612):440-443
pubmed: 27409807
Nat Rev Neurosci. 2005 Jun;6(6):423-34
pubmed: 15928715
Rev Neurosci. 2019 Jan 28;30(2):179-201
pubmed: 30173208
Brain Res. 2018 Aug 15;1693(Pt B):207-213
pubmed: 29360466
Cell Tissue Res. 2015 Aug;361(2):411-26
pubmed: 25722087
Auton Neurosci. 2013 Oct;177(2):199-210
pubmed: 23726157
Nutrients. 2018 Feb 13;10(2):
pubmed: 29438282
Inflamm Bowel Dis. 2016 Feb;22(2):433-49
pubmed: 26689598
Gut. 2014 Aug;63(8):1300-12
pubmed: 24082036
J Surg Res. 2017 Nov;219:214-221
pubmed: 29078884
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
Gut. 2017 Feb;66(2):258-269
pubmed: 26565000
Neuron. 2015 Jan 21;85(2):289-95
pubmed: 25578362
Sci Rep. 2019 Dec 20;9(1):19556
pubmed: 31862918
Gastroenterology. 2007 Sep;133(3):918-25
pubmed: 17678654
Br J Pharmacol. 2016 Jul;173(13):2095-110
pubmed: 26472268
Am J Physiol Gastrointest Liver Physiol. 2018 Oct 1;315(4):G473-G483
pubmed: 29927320
World J Gastroenterol. 2011 Mar 14;17(10):1261-6
pubmed: 21455324
Brain Behav Immun. 2020 Jul;87:93-94
pubmed: 32335192
Neuroendocrinology. 2020;110(1-2):139-146
pubmed: 31280267
Cell Rep. 2020 Sep 8;32(10):108100
pubmed: 32905782